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Introduction
The gabarapl1 (gabarap like-1) gene was originally discovered in our laboratory as an early estrogen-regulated gene in guinea pig endometrial glandular epithelial cells (GEC) and was therefore previously named gec1 [1, 2] .
The GABARAPL1 protein is composed of 117 amino acids, which are highly conserved between species, and belongs to a small family of proteins, called the GABARAP family, based on sequence identity between the different members. In addition to GABARAPL1, this family also includes GABARAP (GABA A receptor-associated protein), and GABARAPL2/GATE-16 (GABARAP like-2 protein/ Golgi-associated ATPase enhancer of 16 kDa), which share 87% and 61% identity with GABARAPL1, respectively [3, 4] . GABARAPL1 also presents a rather low homology with the MAP-LC3B (microtubuleassociated protein light chain 3B) protein [5] .
Very few studies regarding the expression of this protein have been conducted because of its strong identity with GABARAP. Indeed, the existence of an antibody that can discriminate between these two proteins has not yet been proven. The tissue specific expression of the gabarapl1 mRNA, obtained with the use of a probe designed against a unique portion of the 3 0 UTR, however, reveals that gabarapl1 is ubiquitously expressed with the highest expression levels observed in the brain. Gabarapl1 mRNA is, in fact, the most strongly expressed amongst its closest counterparts in multiple rat brain areas ranging from the olfactory bulb to the brainstem and cerebellum, as well as in the spinal cord. In these structures, gabarapl1 mRNA seems to be localized in neurons and particularly in motoneurons and neuroendocrine neurons [6, 7] .
The emergence of new GABARAPL1 protein partners has allowed us to hypothesize the role of this small protein in major cellular processes. GABARAPL1 has been shown to interact in vitro Abbreviations: 17-AAG, 17-N-Allylamino-17-demethoxygeldanamycin; GABA A , g-aminobutyric acid, type A; GABA A R, g-aminobutyric acid, type A receptor; with two essential membrane receptors in the brain: GABA A R (gamma-aminobutyric acid, type A receptor) and KOR (kappa opioid receptor) [8e10] . GABARAPL1 could thus participate in neuronal signal transmission by aiding in the transport of these membrane receptors to the cell surface. Tubulin and NSF (N-ethylmaleimide sensitive factor), two other GABARAPL1 binding partners, may contribute to the intracellular trafficking of the two aforementioned receptors [8e11]. Tubulin is a major cell component of the cytoskeleton, known to aid in the guidance of intracellular trafficking, and NSF is already known to play a role in trafficking of neuronal receptors such as AMPA (a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) type glutamate and b-adrenergic receptors. GABARAPL1, via its interaction with tubulin, is also able to promote tubulin assembly and microtubule bundling [8] . The contribution of GABARAPL1 to intracellular protein transport is not restricted to the brain as demonstrated by its interaction with PX-RICS [Phox-RhoGAP (GTPase-activating protein) involved in the b-catenin-N-cadherin and NMDA (N-methyl-D-aspartate)
receptor signaling], a protein that mediates the transport of the Ncadherin/b-catenin complex from the ER to the Golgi apparatus in HeLa cells [12] .
Due to the high homology between the different members of the GABARAP family, all GABARAPL1 partners outlined above also interact with one or several of the GABARAP family members. Two proteins, namely alpha-synuclein and ARH (Autosomal Recessive Hypercholesterolemia) have been described to interact only with the GABARAPL1 protein but their association with other GABARAP family members has not yet been addressed [13, 14] .
Some studies have reported a low expression of gabarapl1 mRNA in different types of cancers and we recently demonstrated, from the study of a cohort of 265 breast adenocarcinoma biopsies, that patients with a high expression of gabarapl1 mRNA present a lower risk of recurrence [15, 16] . Recently, we also described GABARAPL1 as a new marker of autophagosomes. More precisely, we demonstrated that GABAR-APL1 is cleaved in the cells to produce its mature form, is linked onto phospholipids and associates with autophagic vesicles [17, 18] . Moreover, it has been suggested that GABARAPL1 plays a role in selective autophagy, a form of autophagy that targets specific proteins or organelles to be degraded in the lysosomes, due to its association with p62/SQSTM1 (Sequestosome 1), NBR1 (Neighbour of Brca1 gene) and Nix1/BNIP3L [BNIP3 like protein (BNIP3: Bcl2/ E1B 19 kDa-interacting protein 3-like protein)], which have all been described as cargo adapters [19e22] .
To search for new functions of the GABARAPL1 protein, we looked for new GABARAPL1 partners in rat brain, a tissue that highly expresses gabarapl1, by using a GST pull-down assay coupled to mass spectrometry. We report here an interaction between GABARAPL1 and the molecular chaperone HSP90 in rat brain and in MCF-7 cells. In cells, a specific inhibition of HSP90 ATPase activity by 17-AAG (17-N-Allylamino-17-demethoxygeldanamycin) disrupts this interaction whereas the use of the potent proteasome inhibitor MG132 (ZLeu-Leu-Leu-al) protects GABARAPL1 from degradation. GABAR-APL1 can consequently now be defined as a new HSP90 client protein.
Materials and methods

Animals and tissue preparation
All animal use and care protocols were in accordance with institutional guidelines (all protocols were approved and investigators authorized). SpragueeDawley rats were obtained from Charles River Laboratories (L'Arbresle, France).
Rats were anesthetized with an intraperitoneal injection of chloral hydrate 7% (1 ml/200 g), and then perfused as previously described [23] with 0.9% (w/v) NaCl followed by ice-cold 1% (w/v) paraformaldehyde fixative in 0.1 M phosphate buffer. The brains were removed, post-fixed in the same fixative overnight at 4 C, immersed overnight in a 15% (w/v) sucrose solution at 4 C, and then frozen over liquid nitrogen. Brains were serially cut into 10 mm coronal sections on a cryostat-microtome, mounted on gelatinated slides and stored at À40 C until further analysis.
Reagents and antibodies
Cell culture reagents were purchased from Invitrogen (Carlsbad, CA). The following antibodies were used: two different polyclonal anti-GABARAPL1 antibodies, one from Chemicon Millipore (AB15278) for Western blotting experiments and one from Protein Tech Group (11010-1-AP) for immunohistochemistry and immunoprecipitation experiments, polyclonal anti-GFP (Chemicon Millipore, AB3080), monoclonal anti-HSP90 (TebuBio, AC88), monoclonal anti-FLAG M2 (SigmaeAldrich, A2220), monoclonal anti-RIP1 (receptor interacting protein 1) (BD Pharmingen, 551041), monoclonal anti-tubulin (Abcam, ab56676) and polyclonal antiactin (Sigma, A5060). MG132 (Z-Leu-Leu-Leu-al) (SigmaeAldrich, C2211), bortezomib (Santa Cruz Biotechnology sc-217785), lactacystin (Santa Cruz Biotechnology, sc-3575) and 17-(Allylamino)-17-demethoxygeldanamycin (17-AAG) (SigmaeAldrich, A8476) were prepared in DMSO. The human recombinant HSP90b protein was purchased from Cayman Chemical (10342).
Plasmids
The pGEX-4T-2, pGEX-4-T2 GST-GABARAPL1 and pGEX-4-T2 GST-GABARAPL1 (22-117) vectors expressing the glutathione Stransferase (GST) enzyme, the GST-GABARAPL1 and the GST-GABARAPL1 (22-117) proteins were described previously [8] . The gabarapl1 coding sequence flanked by two tag sequences, coding for a Flag peptide and a six-histidine tail, respectively, was cloned into the XbaI and BamH1:BglII sites of the pSBet vector [24] , allowing expression of the FLAG-GABARAPL1-6HIS protein in Escherichia coli bacteria. The pGST-HSP90a and the pGFP-HSP90b vectors were kindly provided by Dr. Altieri (University of Massachusetts Medical School, Worcester, USA) and Dr. J. Kim (Korea University, Seoul, South Korea), respectively.
Cell culture and transfection
The HEK293 (Human Embryonic Kidney 293) (ATCC, CRL-1573) and MCF-7 (Michigan Cancer Foundation) (ATCC, HTB-22) cells were cultured in DMEM (Dulbecco's Minimum Essential Medium, Invitrogen, 11880) supplemented with 2 mM L-Glutamine (Invitrogen, 25030-032), 100 mg/ml penicillin, 100 mg/ml streptomycin (Invitrogen, 15140) and 10% (for the HEK293 cells) or 5% (for the MCF-7 cells) foetal bovine serum (FBS, Invitrogen, 10270-106) and kept in a 5% CO 2 incubator at 37 C. The MCF-7-FLAG-GABARAPL1-6HIS and MCF-7-Dsred-GABARAPL1 cell lines were previously created [17] . These cell lines were maintained in complete medium supplemented with 100 mg/ml Hygromycin B (PAA, P02-015) and 100 mg/ml G418 (PAA, P02-012), respectively. TransFast reagent (Promega, E2431) was used to transiently transfect HEK293 cells plated in 10 cm-diameter culture dishes ( Total proteins extracts from 6-well plates were used for immunoblotting. Cells cultured in 24-well plates were analysed by confocal microscopy.
Expression, production and purification of fusion proteins
The pGST-HSP90a vector, the pGEX-4-T2 GST-GABARAPL1, the pGEX-4-T2 GST-GABARAPL1 (22-117), the pGEX-4-T2 GST-GABARAP and the pGEX-4-T2 GST-GATE-16 vectors were used to transform BL21-DE3 E.coli. The different fusion proteins expressed from these vectors were induced with 0.5 mM isopropyl-b-D-thiogalactopyranoside (IPTG) for 2 h. The bacterial pellet, obtained by centrifugation (5000 g, 10 min, 4 C), was resuspended in 800 ml of PBS (0.137 M NaCl, 3.3 mM KCl, 10 mM Na 2 HPO 4 , 1.8 mM KH 2 PO 4 ) supplemented with 1% (v/v) Triton X-100, 1 mM protease inhibitors (SigmaeAldrich P8340) and 0.2 mM phenylmethylsulfonyl fluoride (PMSF). After sonication (Sonics and Materials) (3 times for 15 s), a second centrifugation (10 000 g, 20 min, 4 C) was performed to clear the lysate. The GST-fusion proteins contained in the supernatant were bound to 100 ml of glutathione-agarose beads (SigmaeAldrich, G4510) for 2 h at 4 C under agitation. The beads were then washed 3 times in PBS supplemented with 500 mM NaCl.
The FLAG-GABARAPL1-6HIS protein was purified using a Ni-NTA Purification System (Qiagen 30210) according to the manufacturer's instructions. After induction of the pool of the proteins with IPTG, bacterial cells were incubated in lysis buffer (20 mM TriseHCl, 20% (v/v) glycerol, 0.2 mM EDTA, 500 mM KCl, 10 mM imidazole, 10 mM b-mercaptoethanol, 1 mg/ml lysozyme) for 30 min on ice. After sonication (3 times for 15 s) and centrifugation (16 000 g, 30 min, 4 C), the cleared lysate was incubated with Ni-NTA resin for 2 h at 4 C. After centrifugation (5000 g, 5 min, 4 C), the resin was washed 3 times in a wash buffer [20 mM TriseHCl, 20% (v/v) glycerol, 0.2 mM EDTA, 100 mM KCl, 20 mM imidazole, 10 mM bmercaptoethanol, 0.5 mM PMSF]. The FLAG-GABARAPL1-6HIS protein was then eluted with increasing concentrations of imidazole (50e250 mM).
GST pull-down affinity
Total protein lysates from HEK293 cells transiently transfected by the pGFP-HSP90b vector or from rat brains (previously cut into small pieces and homogenized with a hand-driven Potter-Elvehjem apparatus) were obtained by incubation on ice for 30 min in GST pull-down lysis buffer [(10 mM TriseHCl pH 7.6, 100 mM NaCl, 5 mM EDTA, 10 mM MgCl 2 , 0.5% (v/v) NP-40, 1% (v/v) Triton X100, 1 mM protease inhibitors (SigmaeAldrich P8340)] followed by centrifugation (30 min, 16 000 g, 4 C). Five mg of rat brain protein extract were incubated with GST or GST-GABARAPL1 (prepared as previously described) bound to 100 ml of glutathione-agarose beads in GST pull-down lysis buffer overnight at 4 C under constant agitation. After three extensive washes in PBS supplemented with 200 mM NaCl, proteins were eluted in 40 ml of SDS-PAGE loading buffer (78 mM TriseHCl, pH 6.8, 2.5% (w/v) SDS, 12.5% (v/v) glycerol, 6.25% (v/v) b-mercaptoethanol, 0.025% (w/v) bromophenol blue) and separated on a 10% or a 12.5% SDS-PAGE gel. After Coomassie blue staining, seven protein bands of interest were excised from the gel and analysed by mass spectrometry. To test in vitro binding of GABARAPL1 with HSP90, GST pull-down experiments were performed using GST-HSP90a, GST-GABARAPL1 or GST-GABARAPL1 (22-117) fusion proteins (prepared as previously described) immobilized on 100 ml glutathione-agarose beads in combination with either a rat brain protein extract (5 mg) or a HEK293 expressing GFP-HSP90b cell lysate (1 mg) or a purified FLAG-GABARAPL1-6HIS protein (500 ng), or a human recombinant HSP90b protein (5 mg).
Mass spectrometry analysis
Bands of interest were excised manually from the SDS-PAGE gel and cut into 1 mm 3 pieces. The gel fragments were then washed in 
Immunoprecipitation
Total protein lysates from MCF-7 cells or rat brains (previously cut into small pieces and homogenized with a hand-driven PotterElvehjem apparatus) were obtained by incubation on ice for 30 min in immunoprecipitation buffer [50 mM HEPES, pH 7.6, 150 mM NaCl, 5 mM EDTA, 0.1% (v/v) NP-40, 1 mM protease inhibitors (SigmaeAldrich P8340)] followed by a centrifugation (30 min, 16 000 g, 4 C). The supernatants were then incubated with 30 ml of magnetic beads (Dynabeads Protein G Invitrogen, 100-03D) together with 2 mg of the indicated antibody [anti-FLAG M2 (SigmaAldrich) or anti-GABARAPL1 (Protein Tech Group)] under constant agitation at room temperature for 10 min. MCF-7-FLAG-GABAR-APL1-6HIS cell lysate (100 mg) or rat brain extract (500 mg) were then added to the beads and incubated for 30 min at room temperature while agitating. After three washes in PBS, immunocomplexes were eluted in 2X SDS loading buffer and loaded on a 12.5% SDS-PAGE gel. The target proteins were then detected by immunoblotting as described below.
Western blot analysis
Whole cell lysates (40 mg) were separated by SDS-PAGE on a 10%, 12.5% or a 15% gel before transfer to an Immobilon-P PVDF membrane (Dutscher, 44088). The membranes were blocked with 5% (w/v) skim milk in 0.1% Tween 20/TBS (10 mM TriseHCl, pH 7.4, 150 mM NaCl, 0.1% (v/v) Tween 20) and incubated at 4 C overnight with primary antibodies in antibody block buffer (0.5% (w/v) skim milk in 0.1% (v/v) Tween 20/TBS). The following antibodies were used at the indicated dilution: polyclonal anti-GABARAPL1 (Chemicon Millipore) (1:2000), polyclonal anti-GABARAPL1 (Protein Tech Group) (1:1000), polyclonal anti-HSP90b (1:3000), monoclonal anti-HSP90 (1:2000), polyclonal anti-GFP (1:5000), monoclonal anti-RIP1 (1:2500), monoclonal anti-tubulin (1:10 000) and polyclonal anti-actin (1:10 000). Immunoreactive bands were detected using goat horseradish peroxydase (HRP)-coupled secondary anti-mouse (P.A.R.I.S, BI 2413C) or anti-rabbit (P.A.R.I.S, BI 2407C) antibodies (1:20 000 in antibody block buffer) and ECL Plus reagent (GE Healthcare Life Sciences, RPN2132), according to the manufacturer's protocol.
Immunohistochemistry
Rat brain sections were rinsed in PBS supplemented with 0.3% (v/v) Triton X100 and incubated overnight with the primary anti-GABARAPL1 antibody (1:200) diluted in PBS containing 0.3% (v/v) Triton X100, 1% (w/v) bovine serum albumine, 10% (w/v) skim milk and 0.01% (w/v) sodium azide at room temperature. The labeling was then revealed with a secondary goat anti-rabbit IgG conjugated Alexa Fluor-488 (1:800, Invitrogen) for 1 h at room temperature. Then, sections were incubated, under the same conditions, with the monoclonal anti-HSP90 (1:400) antibody diluted in PBS containing 0.3% (v/v) Triton X100 and revealed with a donkey anti-mouse IgG conjugated to Alexa Fluor-555 (1:800, Invitrogen). Fluorescent sections were then observed using a confocal microscope described below.
Confocal microscopy analysis
Cells grown on coverslips were fixed in PBS-paraformaldehyde 4% (w/v) (PFA, SigmaeAldrich, P6148) for 15 min and washed once with PBS. Cells and labeled brain sections were then analysed using a fluorescence laser scanning confocal microscope Fluoview FV1000 BX (Olympus, France). Images were obtained through a DP 75 numeric camera using the Fluoview FV1000 software (Olympus, France).
Results
Identification of new GABARAPL1-interacting partners
In order to further understand the biological functions of GABARAPL1, we searched for new interacting partners of this protein using rat brain protein extracts in a GST pull-down experiment coupled to mass spectrometry. Proteins eluted from the GST pull-down experiments were separated by SDS-PAGE and visualized by Coomassie staining. Many proteins displayed a specific interaction with GST-GABARAPL1 (Fig. 1D) . Seven intensive bands not present or of lower intensity in the control tracks [corresponding to GST alone (Fig. 1A) , GST incubated with rat brain extract (Fig. 1B) and GST-GABARAPL1 alone (Fig. 1C)] were excised from the gel and analysed by mass spectrometry. Of the various potential GABARAPL1 protein partners identified, eleven were confirmed by both MS and MS/MS analysis (Table 1) . Among all identified proteins, we recovered tubulin, a protein already known to interact in vitro with GABARAPL1 [8] and clathrin heavy chain, a protein described to associate with GABARAP [25] . The HSP90b protein corresponding to the 84 kDa heat shock protein (Q1PSW2) identified in band n 4 (Fig. 1D ) by both MS (Mascot score: 63) and MS/MS (two peptides with respectively a Mascot score of 63 and 61) was particularly interesting due to its implication in numerous cellular processes such as protein folding, stress response, signal transduction and tumor progression [26e28]. In the rat central nervous system (CNS), HSP90 is markedly expressed throughout all neuronal subpopulations suggesting its functional role in the CNS [29] . Moreover, a recent global analysis of the human autophagic gene network has identified new GABARAPL1 protein partners including the HSP90 protein in HEK293 cells using immunoprecipitation coupled to mass spectrometry [30] .
GABARAPL1 interacts with HSP90
GST pull-down experiments
A variety of GST pull-down experiments using GST and different GST-fusion proteins [GST-HSP90a, GST-GABARAPL1, GST-GABAR-APL1 (22-117)] were used to confirm the interaction between GABARAPL1 and both HSP90a and b isoforms. A GST pull-down assay using recombinant bacterial GST-GABARAPL1 and rat brain protein extracts coupled to Western blot analysis confirmed the in vitro interaction of this protein with HSP90 ( Fig. 2A) . A GST pulldown assay followed by Western blot analysis using an anti-GFP antibody also demonstrated an interaction between these two proteins in HEK293 cells transiently expressing GFP-HSP90b (Fig. 2B) .
Two different GST pull-down experiments utilizing either GST-GABARAPL1 and the human recombinant HSP90b protein or GSTHSP90a and the purified FLAG-GABARAPL1-6HIS protein demonstrated the direct interaction between GABARAPL1 and HSP90a or HSP90b (Fig. 2C, D) .
Mansuy and colleagues have demonstrated, using a deletion mutant of GABARAPL1 in a GST pull-down experiment, that the 22 amino-terminal residues of GABARAPL1 are necessary for tubulin binding [8] . In order to determine if this region of GABARAPL1 is also responsible for its interaction with HSP90b, we subsequently tested the ability of this deletion mutant to interact with HSP90b in a pull-down assay performed with HEK293 GFP-HSP90b cell lysates and with the human recombinant HSP90b protein. The intensity of the signals corresponding to GFP-HSP90b and HSP90b was strongly reduced when using the deletion mutant compared to the wild- Fig. 1 . Identification of new GABARAPL1-interacting proteins by GST pull-down assay coupled to mass spectrometry. GST (A, B) and GST-GABARAPL1 (C, D) were expressed in E.coli and purified by glutathione-agarose affinity chromatography prior to incubation with rat brain protein extracts (B, D). After extensive washing, bound material was resolved by SDS-PAGE (10%) and analyzed by Coomassie staining. Several proteins specifically bound GABARAPL1 and seven bands were excised from the gel to undergo tryptic digestion and mass spectrometry analysis (Table 1) .
type protein, showing that the amino-terminus of GABARAPL1 largely contributes to the interaction with HSP90b (Fig. 2B, C) .
Moreover, a direct interaction between GST-GABARAP or GST-GATE-16 and human recombinant HSP90b protein was also established (Fig. 2E) demonstrating that HSP90b could also have a chaperone effect on other members of the GABARAP family.
Coimmunoprecipitation experiments
To confirm this interaction in vivo, we performed an immunoprecipitation experiment using rat brain extracts and an anti-GABARAPL1 antibody (Protein Tech Group) or an anti-FLAG M2 antibody (SigmaeAldrich) followed by Western blotting using anti-GABARAPL1 (Chemicon, Millipore) and anti-HSP90 antibodies ( Fig. 3) . The anti-GABARAPL1 antibody from Chemicon cross-reacts with GABARAP and GABARAPL1 while the antibody from Protein Tech Group shows little to no cross-reaction with the GABARAP protein under the conditions used (data not shown). In Fig. 3 , we note that the HSP90 protein was coimmunoprecipitated with GABARAPL1, confirming an interaction between HSP90 and GABARAPL1 in rat brain (Fig. 3A) and in MCF-7-FLAG-GABARAPL1-6HIS cells (Fig. 3B) . Three different irrelevant antibodies (antirabbit GFP, anti-rabbit IgG and anti-mouse IgG) were used as immunoprecipitation negative controls. The use of an anti-GABARAPL1 antibody (Chemicon, Millipore) that detects both GABARAPL1 and GABARAP for Western blot analysis showed two bands of different intensity in the brain, a higher and more intense band corresponding to GABARAPL1 and the other one corresponding to GABARAP (Fig. 3A) . This observation also suggests that GABARAP could interact with HSP90 or that GABARAP was coimmunoprecipitated with GABARAPL1. In MCF-7-FLAG-GABARAPL1-6HIS cells, however, the GABARAPL1/HSP90 interaction is indubitable given that GABARAP could not be immunoprecipitated by the anti-FLAG antibody (Fig. 3B ).
GABARAPL1 colocalizes with HSP90
3.3.1. Colocalization in MCF-7-Dsred-GABARAPL1 cells Following demonstration of an in vitro and an in vivo interaction between GABARAPL1 and HSP90, we investigated the possibility of a colocalization of these two proteins in the MCF-7-Dsred-GABARAPL1 stable cell line transiently transfected with a plasmid encoding the GFP-HSP90b protein. This stable cell line overexpresses the red fluorescent Dsred-GABARAPL1 fusion protein, which localizes to perinuclear intracytoplasmic vesicles described to be autophagosomes and lysosomes [17] . Following transfection, the GFP-HSP90b protein was widely expressed throughout the cell, mainly in the cytoplasm, but also displayed punctate staining. Amongst these dots, a partial colocalization of GABARAPL1 with GFP-HSP90b was clearly observed (Fig. 4A ).
Colocalization in rat brain
To study if this colocalization also occurs in vivo, we performed immunohistochemistry on rat brain sections within the dorsal retrosplenial cortex, substantia nigra and reticular nucleus thalamus using anti-GABARAPL1 (Protein Tech Group) and anti-HSP90 antibodies. The anti-GABARAPL1 antibody has been previously used in immunofluorescence staining to detect GABARAPL1 in HT29 cells [31] . These brain areas were previously described to display a strong expression of gabarapl1 mRNA [6, 7] . GABARAPL1 and HSP90 were highly expressed as intracytoplasmic dots and, in agreement with the results obtained in MCF-7-Dsred-GABARAPL1 cells, a partial colocalization was observed. Furthermore, both these proteins also presented a diffuse expression throughout the cytoplasm, where they partially colocalized (Fig. 4B) .
17-AAG promotes proteasome-dependent degradation of GABARAPL1
HSP90 is a chaperone for several client proteins involved in transcriptional regulation, signal transduction and cell cycle control [26, 27] . The HSP90 activity inhibitor 17-AAG, an analogue of geldanamycin, blocks the association of HSP90 with its substrates by disrupting its ATPase function leading to the degradation of these client proteins. The majority of proteins whose stability is regulated by HSP90 are degraded by the proteasome [32, 33] .
Wild-type MCF-7 cells and MCF-7 cells stably expressing the FLAG-GABARAPL1-6HIS fusion protein were treated with 1 mM of 17-AAG with or without the specific proteasome inhibitor MG132 for 15 h. The efficacy of treatment was first verified by immunodetection of the protein RIP1 in MCF-7 cells (Fig. 5A) . The protein RIP1 is a well known HSP90 client protein as proved by disruption of the interaction between these two proteins following geldanamycin treatment. Moreover, geldanamycin-induced degradation of RIP1 was abrogated by MG132 treatment [34] . Similar results were obtained with the GABARAPL1 protein (Fig. 5B) . Two signals were apparent in MCF-7-FLAG-GABARAPL1-6HIS cells in immunoblotting experiments using the anti-GABARAPL1 antibody from Chemicon. The higher molecular weight band corresponded to FLAG-GABARAPL1-6HIS and the lowest one corresponded to GABARAP. Only one signal corresponding to FLAG-GABARAPL1-6HIS was detectable with the anti-FLAG M2 antibody (SigmaeAldrich) (data not shown). The endogenous GABARAPL1 protein is not usually apparent in immunoblot experiments performed on untreated MCF-7 and MCF-7-FLAG-GABARAPL1-6HIS cells. 17-AAG treatment caused a marked decrease in the level of FLAG-GABARAPL1-6HIS protein compared with non-treated cells. The maximal effect of this compound in MCF-7-FLAG-GABARAPL1-6HIS cells is observed after 15 h of treatment (Fig. 5C ). This result indicates that GABARAPL1 may be a client protein for active HSP90 since the molecular chaperoning activity of HSP90 appears to play an important role in the stability of GABARAPL1 in cells. We therefore hypothesized, that following treatment with 17-AAG, the interaction between the two proteins is abolished leading to FLAG-GABARAPL1-6HIS degradation by the proteasome. To confirm our hypothesis, we treated MCF-7-FLAG-GABARAPL1-6HIS cells with the MG132 proteasome inhibitor. This treatment considerably enhanced the level of FLAG-GABARAPL1-6HIS in the cells. Interestingly, double treatment with 17-AAG and MG132 led to the same result, implying that proteasomal inhibition prevents the degradation of GABARAPL1 induced by 17-AAG. As an aside, an additional signal, located between the bands corresponding to FLAG-GABARAPL1-6HIS and endogenous GABARAP, was observed in this experiment. We propose that this signal corresponds to the endogenous GABARAPL1 protein. The treatment of non-transfected MCF-7 cells with MG132 revealed this proteins from dorsal retrosplenial cortex, substantia nigra or reticular nucleus thalamus (schematically represented in two rat brain frontal sections) were analysed by confocal microscopy following immunohistochemistry experiments. Top right images correspond to a 1.5-fold to a 2-fold magnification of the selected cells. Images were acquired at a 120Â magnification for dorsal retrosplenial cortex and substantia nigra and at a 90Â magnification for reticular nucleus thalamus. Each figure represents one of three independent experiments performed with similar results. same new signal, strongly suggesting the enhancement of endogenous GABARAPL1 protein levels, as well.
As shown in Fig. 6A and B, the MG132 effect is maximal at a concentration of 2 mM and after 15 h of treatment. We then used two different proteasome inhibitors (lactacystin and bortezomib) to confirm that this effect is not due to side effects of MG132. As already observed in the MG132 experiments, treatment with either of these two chemicals resulted in an increased expression of FLAG-GABARAPL1-6HIS and the apparition of a signal corresponding to endogenous GABARAPL1 (from 2.5 mM of lactacystin and from 10 nM of bortezomib) (Fig. 6C, D) . We can thus confirm the expression of endogenous GABARAPL1 following proteasomal degradation blockade. Interestingly, unlike GABARAPL1, no variation of GABARAP expression was observed with any of the proteasomal inhibitors tested, suggesting that these two highly related proteins are subjected to different post-translational regulation in cells under the conditions tested (Figs. 5 and 6) .
Consequently, we can conclude that disruption of the chaperoning activity of HSP90 by 17-AAG causes the degradation of exogenous FLAG-GABARAPL1-6HIS and endogenous GABARAPL1 through the proteasome since the use of proteasome specific inhibitors leads to an accumulation of both the FLAG-GABARAPL1-6HIS and GABARAPL1 proteins in the cells.
Finally, we assessed effects of this disruption on the cellular localization and/or expression of Dsred-GABARAPL1 in MCF-7 cells by confocal microscopy (Fig. 7) . Similar to the results obtained by Western blot, 17-AAG treatment led to the reduction of Dsred-GABARAPL1 staining, whereas an opposite effect was observed when cells were stimulated with MG132 and 17-AAG combined with MG132.
Discussion
In this study, a GST pull-down assay followed by mass spectrometry analysis led to the discovery of various new GABARAPL1 partners, opening the door to new functional investigations for this protein. Among these partners, we identified HSP90b as a new GABARAPL1-interacting protein. We also confirmed previously published GABARAPL1 and/or GABARAP protein-interactions. For example, we found the clathrin heavy chain protein, a GABARAP cellular partner that is essential in the formation of coated vesicles [25] . In the brain, neurons regulate the number of postsynaptic receptors, such as GABA A receptors, by internalization in clathrincoated vesicles. Amongst identified proteins in mass spectrometry analysis, we also found the AP-2 (adaptor protein-2) and dynamin (D100) proteins which are known to take part in GABA A receptors endocytosis [35, 36] . Consequently, GABARAPL1 may associate with these three proteins to aid in the turnover of GABA A receptors. Subunits of tubulin were also identified, reinforcing the hypothesis that GABARAPL1 mediates intracellular trafficking of proteins, such as GABA A or k-opioid receptors, in the brain [8, 9, 11] . We then focused our attention on the potential new GABAR-APL1-interacting partner HSP90b because of its involvement in various cellular processes including cell proliferation, differentiation and apoptosis [37] . HSP90 is a highly conserved and abundant protein in eukaryotic cells, corresponding to 1e2% of total cellular proteins under non-stress conditions [26] . There are two major cytoplasmic isoforms of HSP90, HSP90a and HSP90b, which share approximately 86% identity in vertebrate species [38] . HSP90 is a molecular chaperone that interacts with multiple co-chaperones to assure the maintenance of protein quality in the cell by regulating the balance between folding and degradation of proteins. A growing list of HSP90 client proteins, which now includes several hundreds of proteins, is currently maintained by the laboratory of Didier Picard [39] . HSP90 client proteins include a variety of transcription factors such as mutated p53, protein kinases (Akt, ErbB2, Raf, RIP1), cell surface receptors and cellular enzymes. The NH 2 -terminal ATP/ADP binding pocket of HSP90 is important for its folding function as a chaperone. Moreover, this domain is the binding site of specific drugs including ansamycin antibiotics such as geldanamycin and its modified derivative 17-AAG [40] . These drugs competitively inhibit ATP binding and induce a conformational change in the HSP90 molecule that results in a destabilization of its interaction with its chaperoned proteins and their subsequent degradation through the proteasome pathway [41] . These drugs also display antitumor activity in numerous animal tumor models and their effects are currently being evaluated in several clinical trials [33,42e44] .
In this work, we demonstrate that GABARAPL1 interacts directly with both HSP90a and b isoforms as demonstrated by use of either purified GST-HSP90a or HSP90b proteins in GST pull-down assays and by use of an antibody directed against the two isoforms in coimmunoprecipitation experiments. In the immunoprecipitation experiment performed using rat brain extracts, an antibody directed against GABARAPL1 versus GABARAP was used to immunoprecipitate GABARAPL1 and an antibody recognizing the two proteins was used in immunoblot. In the brain, the GABARAP protein, although to a lesser extent than GABARAPL1, was immunoprecipitated disallowing us to exclude the possibility of an interaction between GABARAP and HSP90 or between GABARAPL1 and GABARAP. However, in the MCF-7-FLAG-GABARAPL1-6HIS cellular model, the specific interaction between GABARAPL1 and HSP90 is confirmed with the use of an anti-FLAG antibody, which specifically immunoprecipitates GABARAPL1. Moreover, the interaction between GABARAP or GATE-16 and HSP90b was confirmed by in vitro pull-down experiments and was also observed by Behrends et al. in HEK293 cells [30] . This same study revealed, on one hand, a potential interaction between HSP90a and/or b isoforms and all other Atg8 family members, GATE-16, LC3A, LC3B and LC3C and on the other hand, the interaction between GABARAPL1 and other HSP proteins such as HSP70, HSP60 and HSP105.
Mansuy et al. previously demonstrated that the first 22 aminoterminal residues of GABARAPL1 are implicated in tubulin binding [8] . Here, we show that the presence of this basic N-terminal region (pHi 9.6) allows for a stronger interaction between GABARAPL1 and the acidic HSP90 protein (pHi 5). Distribution of both GABARAPL1 and HSP90 proteins was analysed in MCF-7 stably expressing Dsred-GABARAPL1 and in three rat brain regions known to express high levels of gabarapl1 mRNA (retrosplenial cortex, substantia nigra and reticular nucleus thalamus). Experiments performed in MCF-7-Dsred-GABARAPL1 cells revealed a partial colocalization of Dsred-GABARAPL1 and GFP-HSP90b in intracytoplasmic perinuclear dots. A similar partial colocalization was found in the two rat brain regions studied by immunohistochemistry.
The role of the association between GABARAPL1 and HSP90 was established by the use of the HSP90 activity specific inhibitor 17-AAG. Following disruption of the interaction between the two proteins, the degradation of GABARAPL1 was demonstrated to be mediated by the proteasome as established by the use of various potent proteasome inhibitors. Interestingly, unlike GABARAPL1, GABARAP protein levels were not affected by the different treatments despite the fact that GABARAP might interact with HSP90, highlighting a major difference in the regulation of these two closely related homologues. We have demonstrated, using quantitative RT-PCR experiments an increase of the endogenous gabarapl1 mRNA level in MCF-7 cells treated by MG132 (data not shown). Moreover, gene profiling studies of prostate cancer cells treated with MG132 and pancreatic cancer cells treated with bortezomib revealed an up-regulation of gabarapl1 and lc3 mRNA [45, 46] . However, in our MCF-7-FLAG-GABARAPL1-6HIS model, the rate of synthesis of the fusion protein increases independently of the transcriptional activation. On the other hand, the increase of the endogenous GABARAPL1 protein level is due to a regulation of its stability associated with a transcriptional regulation of the gabarapl1 gene. Recent studies have demonstrated that inhibition of proteasomal degradation by specific inhibitors induces autophagy, identified by accumulation of LC3B-II, the lipidated form of LC3B that localizes to autophagosomes [47e49]. It is now obvious that these two major routes of degradation are intimately linked. In particular, impairment of degradation by the proteasome pathway causes induction of autophagy [50] . Surprisingly, no presence of the GABARAPL1eII form, already observed in cells by Chakrama et al. in autophagic conditions [17] , is detectable in our experiments, suggesting that GABARAPL1 is not associated to autophagic vesicles following the inhibition of proteasomal activity. These observations therefore describe a differential regulation of GABARAPL1 and LC3B in presence of proteasome inhibitors.
Generally, prior ubiquitinylation of the majority of HSP90 client proteins is required for them to be recognized and subsequently delivered to the proteasome. Some oncosuppressive client proteins, however, such as p53, display a ubiquitin-independent degradation by the proteasome [51] . Preliminary results show that GABARAPL1 is not ubiquitinylated as shown for LC3B (data not shown). Indeed, LC3B can be processed by the 20S core proteasome in a ubiquitinindependent manner in vitro and this degradation is inhibited by its interaction with p62, a mediator of autophagic proteolysis [52] . Concerning GABARAP, Chen et al. suggest that GABARAP does not undergo the ubiquitinylation process and is not degraded through the proteasome after lactacystin treatment in rat cultured hippocampal neurons [53] .
In this report, we successfully screened for novel GABARAPL1 binding partners by performing a simple pull-down assay coupled to mass spectrometry, demonstrating that GABARAPL1 associates with the HSP90 protein and providing evidence for a direct interaction between these two proteins. This study shows, for the first time, that HSP90 protects GABARAPL1 from its proteasomal degradation and therefore increases its stability in MCF-7 cells. These findings provide new and interesting information about the GABARAPL1 turnover within the cell.
